Subject: Specialised Services Circular (SSC 2433)
Sent on behalf of: Chair of the SW Specialised Service Circular Group

Dear Colleagues,

Please find attached the following Specialised Services Circular(s):

SSC Number	SSC Title	Trusts approved to prescribe in accordance with the SSC, providing appropriate internal governance arrangements are in place
SSC 2433	Rituximab in the management of Thrombotic Thrombocytopenic Purpura TTP	University Hospitals Bristol & Weston NHS FT only South West Commissioned TTP Specialist Centre Blueteq enabled at All South West Acute Trusts

Is an implementation plan required from all SW trusts (regardless of commissioned status) for this SSC? No

For all other South West region trusts this is for information only.

Trusts should ensure that use is registered on the Blueteq system (if appropriate).

Treatment will only be funded where the drugs minimum dataset is fully and accurately populated.

Please direct any queries to: england.speccomm-southwest@nhs.net

Specialised Commissioning South West
NHS England
360 Bristol
Marlborough Street
Bristol
BS1 3NX
Email: england.speccomm-southwest@nhs.net

14th October 2022

All Chief Executives

All Medical Directors

All Chief Pharmacists

NHS England Clinical Commissioning Policy: Rituximab in the management of Thrombotic Thrombocytopenic Purpura TTP

NHS England has approved for immediate implementation the Clinical Commissioning Policy for Rituximab in the management of Thrombotic Thrombocytopenic Purpura (TTP). The policy has been commissioned as an in-year service development with no budget impact as rituximab in TTP is established as the standard of care, and expenditure has been accounted for in the recent commissioning of the new regional TTP Specialist Centres.

Rituximab, when used in the management of TTP as laid out in the clinical commissioning policy, is funded as a 'cost and volume' high cost tariff-excluded drug.

All patients who are prescribed this product must be registered on Blueteq. There are separate forms for acute and chronic cases. Commissioners recognise that registration of acute cases might not necessarily occur prior to treatment but providers should seek to register any such use at the earliest subsequent opportunity.

This letter gives the required one month's notice as per Schedule 2 Part G (Other Local Agreements, Policies and Procedures) of your Specialised Services contract for prior approval for this treatment/indication. From one month of the date specified above, NHS England will only reimburse these treatments for patients that have been confirmed as meeting the eligibility criteria via the formal Prior Approval Scheme (i.e. Blueteq). You may wish to use the prior approval mechanism earlier than this to expedite access to this drug.

The published policy can be found here: https://www.england.nhs.uk/specialised-commissioning-document-library/routinely-commissioned-policies/

I should be grateful if this letter could be circulated to relevant clinical and contracting teams to aid awareness and implementation.

With best wishes,

Dr Peter Wilson
Medical Director (Commissioning)

Tracey Williams
Principal Pharmacist